PURPOSE: To evaluate the feasibility and toxicity of perioperative intensity-modulated brachytherapy (IMBT) as well as functional outcome in children with therapy-refractory orbital rhabdomyosarcomas (RMS). PATIENTS AND METHODS: Since 1993, children with therapy-refractory orbital RMS have been treated by a multidisciplinary approach combining function-preserving, mostly R1 tumor resection and perioperative IMBT at the University Hospital of Schleswig-Holstein, Germany. All children with orbital RMS, who were enrolled in this multidisciplinary treatment protocol between 1993 and 2002, were prospectively assessed with respect to evaluation of side effects and functional outcome. RESULTS: Ten children (six boys, four girls) were included. Median age was 6.5 years (range, 1-19 years) at the beginning of our treatment and 6.0 years (range 1-17 years) at diagnosis. All children were in Intergroup Rhabdomyosarcoma Study Group (IRSG) group III and had embryonal subtype. Estimated 5-year survival was 62% +/- 18%. There was no radiation-related toxicity grade 3 or 4 observed. The eyes were primarily preserved in all cases. One child underwent secondary orbital exenteration 10 months after completion of IMBT. Visual acuity could be preserved apart from one child developing significant visual deterioration due to radiation cataract grade 2. The cosmetic results were good or very good in eight and moderate in two children. Four children died of their disease. CONCLUSION: This interdisciplinary, individually tailored and function-preserving treatment procedure has proven to be a well-tolerated therapeutic option in cases with refractory orbital RMS. It provides both improvement of local tumor control and quality of life.
PURPOSE: To evaluate the feasibility and toxicity of perioperative intensity-modulated brachytherapy (IMBT) as well as functional outcome in children with therapy-refractory orbital rhabdomyosarcomas (RMS). PATIENTS AND METHODS: Since 1993, children with therapy-refractory orbital RMS have been treated by a multidisciplinary approach combining function-preserving, mostly R1 tumor resection and perioperative IMBT at the University Hospital of Schleswig-Holstein, Germany. All children with orbital RMS, who were enrolled in this multidisciplinary treatment protocol between 1993 and 2002, were prospectively assessed with respect to evaluation of side effects and functional outcome. RESULTS: Ten children (six boys, four girls) were included. Median age was 6.5 years (range, 1-19 years) at the beginning of our treatment and 6.0 years (range 1-17 years) at diagnosis. All children were in Intergroup Rhabdomyosarcoma Study Group (IRSG) group III and had embryonal subtype. Estimated 5-year survival was 62% +/- 18%. There was no radiation-related toxicity grade 3 or 4 observed. The eyes were primarily preserved in all cases. One child underwent secondary orbital exenteration 10 months after completion of IMBT. Visual acuity could be preserved apart from one child developing significant visual deterioration due to radiation cataract grade 2. The cosmetic results were good or very good in eight and moderate in two children. Four children died of their disease. CONCLUSION: This interdisciplinary, individually tailored and function-preserving treatment procedure has proven to be a well-tolerated therapeutic option in cases with refractory orbital RMS. It provides both improvement of local tumor control and quality of life.
Authors: A Fiorillo; R Migliorati; P Vassallo; G Canale; F Tranfa; I Fariello; C De Chiara; R D'Amore; P Muto; G Bonavolontà Journal: Radiother Oncol Date: 1999-11 Impact factor: 6.280
Authors: Stephanie E Combs; Stephan Konkel; Christoph Thilmann; Jürgen Debus; Daniela Schulz-Ertner Journal: Strahlenther Onkol Date: 2007-02 Impact factor: 3.621
Authors: Beate Timmermann; Andreas Schuck; Felix Niggli; Markus Weiss; Antony Jonathan Lomax; Eros Pedroni; Adolf Coray; Martin Jermann; Hans Peter Rutz; Gudrun Goitein Journal: Int J Radiat Oncol Biol Phys Date: 2006-11-02 Impact factor: 7.038
Authors: M D Wharam; J J Hanfelt; M C Tefft; J Johnston; L G Ensign; J Breneman; S S Donaldson; C Fryer; E A Gehan; R B Raney; H M Maurer Journal: Int J Radiat Oncol Biol Phys Date: 1997-07-01 Impact factor: 7.038
Authors: Lama Jurdy; Johanus H M Merks; Bradly R Pieters; Maarten P Mourits; Roel J H M Kloos; Simone D Strackee; Peerooz Saeed Journal: Saudi J Ophthalmol Date: 2013-07
Authors: Frank Heinzelmann; Daniela Thorwarth; Ulf Lamprecht; Theodor W Kaulich; Jörg Fuchs; Guido Seitz; Martin Ebinger; Rupert Handgretinger; Michael Bamberg; Martin Weinmann Journal: Strahlenther Onkol Date: 2011-10-29 Impact factor: 3.621
Authors: Martin T King; Laszlo Voros; Gil'ad N Cohen; Ryan M Lanning; Ian Ganly; Chibuzo C O'Suoji; Suzanne L Wolden Journal: Brachytherapy Date: 2016-08-12 Impact factor: 2.362
Authors: Beverly Raney; Winston Huh; Douglas Hawkins; Andrea Hayes-Jordan; Lynn Million; David Rodeberg; Lisa Teot; James Anderson Journal: Pediatr Blood Cancer Date: 2012-09-07 Impact factor: 3.167